The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma.
Suppramote O, Prasopporn S, Aroonpruksakul S, Ponvilawan B, Makjaroen J, Suntiparpluacha M, Korphaisarn K, Charngkaew K, Chanwat R, Pisitkun T, Okada S, Sampattavanich S, Jirawatnotai S.
Suppramote O, et al. Among authors: korphaisarn k.
Front Oncol. 2022 May 17;12:877194. doi: 10.3389/fonc.2022.877194. eCollection 2022.
Front Oncol. 2022.
PMID: 35664774
Free PMC article.